No Data
No Data
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday
Express News | Applied Therapeutics Inc : UBS Cuts Target Price to $2 From $13
Express News | Applied Therapeutics Inc : UBS Cuts to Neutral From Buy
Applied Therapeutics Price Target Lowered to $5 From $14 at Baird
Applied Therapeutics CRL a 'Major Setback,' Says William Blair
No Data
No Data